Health & Safety Industry Today
Coronary Heart Disease Diagnostic Imaging Device Market to Reach USD 11.9 Billion by 2034, Growing from USD 6.5 Billion in 2025 - SRI
London, UK - August 2026 | Strategic Revenue Insights Inc. - European regulators have staggered the deadlines for medical device manufacturers to complete conformity assessment under the region's device framework, giving higher-risk implantable devices until the end of 2027 and medium- and lower-risk devices until the end of 2028, and that extended but uneven runway is keeping regulatory and clinical evidence spending elevated across imaging device portfolios. The global coronary heart disease diagnostic imaging device market was valued at USD 6.5 billion in 2025 and is projected to reach USD 11.9 billion by 2034, expanding at a CAGR of 7.00% during the forecast period, according to a new report from Strategic Revenue Insights Inc. The analysis was led by lead analyst Rohan Mehta, drawing on primary interviews with cardiologists, radiologists, and hospital procurement stakeholders, combined with secondary research spanning Asia Pacific, North America, Latin America, Europe, and Middle East & Africa.
Key Takeaways
- The market is valued at USD 6.5 billion in 2025 and is forecast to reach USD 11.9 billion by 2034, a CAGR of 7.00%.
- Imaging Systems & Equipment hold the largest product share, while Software & AI Analysis Tools are the fastest-growing segment.
- AI integration into imaging devices is improving diagnostic accuracy and speed, reshaping how coronary heart disease is screened and diagnosed.
- North America leads the market on advanced healthcare infrastructure and high adoption of diagnostic technologies, while Asia Pacific is the fastest-growing region.
- GE HealthCare, Siemens Healthineers, and Philips Healthcare are among the top companies shaping the competitive landscape.
Full report access: https://www.strategicrevenueinsights.com/industry/coronary-heart-disease-diagnostic-imaging-device-market
A Regulatory Reset Meets a Wave of AI-Driven Innovation
The European regulatory timeline extension has reshaped near-term compliance planning without loosening the underlying safety bar: post-market clinical follow-up obligations remain fully in force even as manufacturers get more time to complete certification. Notified body capacity constraints have kept certification queues tight through 2025 and 2026, prompting manufacturers to rationalize legacy product portfolios rather than renew every device, while the withdrawal of the original sell-off restriction means compliant devices already on the market can keep circulating without a fixed cutoff.
Against that regulatory backdrop, the underlying clinical need keeps growing. Aging populations and rising procedure volumes are expanding the installed base and consumable demand for imaging devices, while minimally invasive and image-guided techniques continue displacing open procedures in favor of more device-intensive care pathways. Hospital capital replacement cycles, combined with the migration of procedures to outpatient settings, are sustaining steady equipment turnover.
Artificial intelligence is the other major force at work, with AI and machine learning integration into imaging devices enabling faster, more accurate diagnosis and improving patient outcomes. This is running alongside rising demand for portable and point-of-care imaging devices for emergency and remote settings, and a parallel push toward more sustainable, eco-friendly manufacturing practices across the sector.
Market Segmentation
By Modality: The market spans Coronary CT Angiography, Cardiac MRI, Nuclear Imaging, Echocardiography, Invasive Coronary Angiography, Intravascular Ultrasound & OCT, and Fractional Flow Reserve Systems, each suited to different diagnostic needs. Coronary CT Angiography is gaining popularity for its non-invasive, high-accuracy profile in early detection, while Invasive Coronary Angiography remains the gold standard for high-risk patients and Echocardiography continues to serve as a cost-effective cornerstone of both screening and follow-up.
By Product: Imaging Systems & Equipment hold the largest share, driven by continuous technological advancement and demand for accurate diagnostic solutions, while Software & AI Analysis Tools are the fastest-growing segment as AI integration reshapes how imaging data is interpreted. Contrast Agents and Accessories & Consumables remain essential supporting categories across diagnostic procedures.
By Application: Screening & Risk Stratification and Diagnosis & Severity Assessment are described as critical applications enabling early detection and guiding treatment decisions, while Interventional Guidance supports complex procedures requiring real-time imaging and Post-Procedure Follow-Up is a growing area of focus as personalized medicine drives demand for more detailed, patient-specific imaging insights.
By End Use: Hospitals are the largest end-use setting, reflecting high cardiac procedure volumes and the need for advanced diagnostic capability, while Cardiac Catheterization Labs rely heavily on imaging to guide interventional procedures. Diagnostic Imaging Centers and Ambulatory Care Centers are both expanding as outpatient and patient-centered care models gain ground.
Regional Outlook
North America leads the global market, supported by advanced healthcare infrastructure and high adoption of diagnostic technologies, while Asia Pacific is experiencing rapid growth driven by expanding healthcare infrastructure and rising coronary heart disease prevalence. Latin America is also highlighted as offering significant growth potential given its expanding healthcare infrastructure, alongside Europe and Middle East & Africa, which round out the report's full regional scope.
Competitive Landscape
GE HealthCare is named as a leading player, known for advanced imaging systems delivering high diagnostic accuracy and for continuously integrating AI and machine learning into its products. Siemens Healthineers is highlighted for its focus on expanding into emerging markets through a strong distribution network and strategic partnerships. Philips Healthcare offers a comprehensive range of imaging systems and is noted for its focus on sustainability and eco-friendly manufacturing practices, while Canon Medical Systems is recognized for expanding its portfolio of cutting-edge imaging technologies. Other notable companies named in the report include Abbott, Boston Scientific, Bracco Imaging, HeartFlow, Cleerly, and Hitachi, each leveraging research and development and strategic partnerships to address rising demand for advanced diagnostic imaging.
Market Restraints
Regulatory challenges and stringent approval processes for new imaging devices can delay product launches and increase development costs, a pressure reinforced by the EU's staggered conformity assessment deadlines and constrained notified body capacity. The high cost of advanced imaging technologies also limits adoption in resource-constrained settings, while rising competition from alternative diagnostic methods is pushing companies to continuously innovate to maintain their competitive edge.
Related Reports
https://www.strategicrevenueinsights.com/industry/industrial-vision-gateways-market
https://www.strategicrevenueinsights.com/industry/industrial-wearable-devices-market
https://www.strategicrevenueinsights.com/industry/industrial-wireless-transmitters-market
Frequently Asked Questions
How big is the coronary heart disease diagnostic imaging device market?
The market was valued at USD 6.5 billion in 2025 and is projected to reach USD 11.9 billion by 2034, growing at a CAGR of 7.00%.
What is driving growth in the coronary heart disease diagnostic imaging device market?
Growth is driven by rising coronary heart disease prevalence, AI integration into imaging devices, aging populations and rising procedure volumes, and the shift toward minimally invasive, image-guided care pathways.
Which region leads the coronary heart disease diagnostic imaging device market?
North America leads due to advanced healthcare infrastructure and high adoption of diagnostic technologies, while Asia Pacific is the fastest-growing region as healthcare infrastructure expands and disease prevalence rises.
Who are the leading companies in the coronary heart disease diagnostic imaging device market?
Leading companies named in the report include GE HealthCare, Siemens Healthineers, Philips Healthcare, Canon Medical Systems, Abbott, Boston Scientific, Bracco Imaging, HeartFlow, Cleerly, and Hitachi.
About Strategic Revenue Insights Inc.
Strategic Revenue Insights Inc., part of SRI Consulting Group Ltd, is a London-headquartered market intelligence firm that helps organizations across industries and geographies make evidence-based revenue and strategy decisions. The firm produces syndicated research reports and customized consulting engagements built on rigorous market sizing, forecasting, and competitive benchmarking, drawing on a globally connected team of analysts and consultants.
Media Contact Information
Company Name: Strategic Revenue Insights Inc.
Contact Person: Rohit Bhisey
Email: sales@strategicrevenueinsights.com
Phone: +44-787-740-3352
Address: Suite 10, Capital House, 61 Amhurst Road, London, E8 1LL, United Kingdom
Corporate Websites:
www.strategicrevenueinsights.com
www.strategicpackaginginsights.com
https://strategicrevenueinsights.blog/
https://medium.com/@strategic-revenue-insights.inc
https://www.strategicrevenueinsights.com/press-releases
Share on Social Media
Contact Information
Rohit Bhisey
Strategic Revenue Insights Inc.
Suite10 Capital House 61 Amhurst Road,
London
London
United kingdom
E8 1LL
+44-787-740-3352
https://www.strategicrevenueinsights.com/
Other Industry News
Ready to start publishing
Sign Up today!
